BioMarin Pharmaceutical Inc. $BMRN Holdings Lowered by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. reduced its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 45.4% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 222,720 shares of the biotechnology company’s stock after selling 185,495 shares during the quarter. Robeco Institutional Asset Management B.V. owned about 0.12% of BioMarin Pharmaceutical worth $13,363,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in BMRN. Primecap Management Co. CA acquired a new stake in BioMarin Pharmaceutical during the 2nd quarter worth $811,962,000. Caisse de depot et placement du Quebec purchased a new stake in shares of BioMarin Pharmaceutical during the second quarter worth $70,749,000. Bank of New York Mellon Corp acquired a new stake in shares of BioMarin Pharmaceutical in the second quarter valued at about $66,107,000. Edmond DE Rothschild Holding S.A. acquired a new stake in shares of BioMarin Pharmaceutical in the second quarter valued at about $39,312,000. Finally, Palo Alto Investors LP acquired a new stake in shares of BioMarin Pharmaceutical in the second quarter valued at about $39,068,500. Hedge funds and other institutional investors own 98.71% of the company’s stock.

BioMarin Pharmaceutical Stock Down 1.2%

Shares of NASDAQ:BMRN opened at $55.95 on Friday. BioMarin Pharmaceutical Inc. has a 52-week low of $49.26 and a 52-week high of $70.98. The stock has a market cap of $10.83 billion, a P/E ratio of 33.71, a PEG ratio of 0.46 and a beta of 0.22. The business has a fifty day moving average of $61.70 and a two-hundred day moving average of $58.65. The company has a quick ratio of 1.32, a current ratio of 2.39 and a debt-to-equity ratio of 0.56.

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, topping the consensus estimate of $0.95 by $0.25. The business had revenue of $989.71 million for the quarter, compared to analyst estimates of $932.03 million. BioMarin Pharmaceutical had a return on equity of 5.32% and a net margin of 2.14%. The company’s quarterly revenue was up 20.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.44 EPS. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. On average, research analysts expect that BioMarin Pharmaceutical Inc. will post 3.46 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on BMRN shares. UBS Group initiated coverage on shares of BioMarin Pharmaceutical in a research report on Thursday, October 15th. They set a “buy” rating and a $88.00 price target on the stock. Weiss Ratings cut shares of BioMarin Pharmaceutical from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, September 18th. JPMorgan Chase & Co. increased their price objective on shares of BioMarin Pharmaceutical from $86.00 to $87.00 and gave the company an “overweight” rating in a report on Tuesday. BMO Capital Markets reissued an “outperform” rating on shares of BioMarin Pharmaceutical in a research note on Wednesday, September 16th. Finally, Citigroup raised their target price on shares of BioMarin Pharmaceutical from $75.00 to $76.00 and gave the stock a “buy” rating in a research note on Thursday, July 16th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, BioMarin Pharmaceutical has a consensus rating of “Moderate Buy” and an average price target of $88.60.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening rare diseases. The company’s research and development efforts center on genetic and metabolic disorders, where patient populations are often small and treatment options are limited.

BioMarin’s marketed products include Voxzogo (vosoritide) for children with achondroplasia and open growth plates, Palynziq (pegvaliase) and Kuvan (sapropterin dihydrochloride) for phenylketonuria, Brineura (cerliponase alfa) for late-infantile neuronal ceroid lipofuscinosis type 2, Vimizim (elosulfase alfa) for Morquio A syndrome, and Naglazyme (galsulfase) for mucopolysaccharidosis VI.